You are here

Article info

Article menu

Download PDFPDF

Health care delivery, economics and global health care
Original research article
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

Authors

  1. Correspondence to Rola Haroun, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland; Rola.Haroun{at}novartis.com
View Full Text

Citation

McMurray JJV, Trueman D, Hancock E, et al
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
Heart 2018;104:1006-1013.

Publication history

  • Received September 22, 2016
  • Revised October 25, 2017
  • Accepted November 2, 2017
  • First published December 21, 2017.
Online issue publication 
January 18, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/